Biotechnology
Glenmark inks agreement with Canadian biotech SaNOtize to commercialize Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets
* Nitric oxide has antimicrobial properties with direct proven effect on SARS-CoV-2 * Nitric Oxide Nasal Spray (NONS) has been tested in healthy volunteers and patients as part of UK andCanada clinical trials1 MUMBAI, India and VANCOUVER, BC, Aug. 2, 2021 /PRNewswire/ -- Glenmark Pharmaceutic...
2021-08-02 18:45
4308
ElectroPhysiology Frontiers announces appointment of Avi Fischer, M.D. as CEO
MILAN, Aug. 2, 2021 /PRNewswire/ -- ElectroPhysiology Frontiers S.p.A. (EPF), announced that its Board of Directors unanimously appointedAvi Fischer, M.D. as Chief Executive Officer (CEO) of the company and a member of its Board of Directors. EPF is a medical technology company developing an inn...
2021-08-02 18:00
2847
Hummingbird Bioscience Announces UK MHRA Approval for First-in-Human Phase 1 Trial of HMBD-001 in Advanced Cancers
HOUSTON and SINGAPORE, Aug. 2, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the ...
2021-08-02 17:00
1940
Servier Announces Positive Topline Data from the Global Phase 3 Study of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia
TIBSOVO is the first targeted therapy to show improved event-free survival and overall survival in combination with azacitidine compared to azacitidine monotherapy. Safety profile consistent with previously published data in patients with IDH1-mutated acute myeloid leukemia. The study recently ...
2021-08-02 14:00
3336
Antengene Announces the Approval of First-in-Class Oral XPO1 Inhibitor Selinexor in South Korea for the Treatment of Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma
SEOUL, South Korea and SHANGHAI and HONG KONG, Aug. 2, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics i...
2021-08-02 07:29
6394
EC Healthcare and Prenetics Form Strategic Partnership to Pioneer the Future of Medicine
HONG KONG, July 30, 2021 /PRNewswire/ -- EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group inHong Kong, announces that the Group signed a memorandum of understanding with Prenetics Limit...
2021-07-30 15:33
10730
Neukio Biotherapeutics completed its $40m Angel round financing, focusing on the development of iPSC-CAR-NK platform and assets.
SHANGHAI, July 30, 2021 /PRNewswire/ -- Neukio Biotherapeutics, a newly established company, recently announced the completion of its$40m Angel round of financing led byLilly Asia Venture (LAV), with the participation of IDG Capital and Sherpa Investments. The fund will be used mainly for the es...
2021-07-30 08:00
4384
Global Cord Blood Corporation Files Annual Report on Form 20-F
HONG KONG, July 30, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company filed its Annual ...
2021-07-30 04:16
14057
MGI Australia Demo Lab Opens to Support APAC Customers
BRISBANE, Australia, July 29, 2021 /PRNewswire/ -- MGI Tech Co. Ltd.
2021-07-29 19:18
2933
Exyte Empowers the Biopharmaceutical Industry: First ExyCell(R) Facility Launched in Shanghai
STUTTGART, Germany and BERGISCH GLADBACH, Germany, July 29, 2021 /PRNewswire/ -- Exyte has successfully completed the construction of the first ExyCell® facility inChina, the CliniMACS Cell Factory® of Miltenyi Biotec, a global provider of integrated solutions for Advanced Therapy Medical Products...
2021-07-29 16:25
3786
BIOTRONIK Applauded by Frost & Sullivan for Its Disruptive Implantable Cardiac Monitoring Device, BIOMONITOR IIIm
LONDON, July 28, 2021 /PRNewswire/ -- Based on its recent analysis of the Global market for implantable cardiac monitoring devices,Frost & Sullivan recognizesBIOTRONIK with the 2021 Global Enabling Technology Leadership Award. The company's subcutaneous miniature, injectable electrocardiogram (EC...
2021-07-28 18:00
1837
Deep Longevity Repurposes a Blood Aging Clock for Saliva Samples
HONG KONG, July 27, 2021 /PRNewswire/ -- Endurance RP Limited's ("Endurance Longevity" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK) wholly owned subsidiary Deep Longevity, Inc, a leading provider of deep biomarkers of aging and longevity is pleased to ann...
2021-07-27 21:39
14655
Cytiva and Pall Corporation investing 1.5 billion USD over two years to meet growing demand for biotechnology solutions
-- Major investments are expanding manufacturing capacity for life sciences products at 13 Cytiva and Pall Corporation sites helping to meet customer demand. -- New sites opening in US and UK to realize regional manufacturing models. Overall, the companies plan to hire 2000 full-time associates...
2021-07-27 14:05
4502
Deep Longevity Releases an AI-based Predictor of COVID Time-To-Death
HONG KONG, July 26, 2021 /PRNewswire/ -- Endurance RP Limited's ("Endurance Longevity" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK) wholly-owned subsidiary Deep Longevity, Inc, a leading provider of deep biomarkers of aging and longevity is pleased to ann...
2021-07-26 19:08
5887
Hummingbird Bioscience Appoints Renowned Scientist and Medical Oncologist Dr. Thomas J. Lynch to its Board of Directors
HOUSTON and SINGAPORE, July 26, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that internationally renowned scientist and medical oncologist, Dr. Thomas J Lynch, Jr,...
2021-07-26 17:00
1760
Laekna Therapeutics will present two clinical study results in ESMO 2021
SHANGHAI and WARREN, N.J., July 26, 2021 /PRNewswire/ -- Laekna Therapeutics, an emerging innovative pharma company based inChina's "Zhangjiang Pharma Valley" andNew Jersey in the U.S. and focused on developing new groundbreaking innovative therapies to treat cancer and liver diseases, announced ...
2021-07-26 13:26
3623
Antengene and Its Partners Publish Preclinical Data Demonstrating the Encouraging Activity of Selinexor in the Prevention and Treatment of SARS-CoV-2 Infections
SHANGHAI and HONG KONG, July 26, 2021 /PRNewswire/ -- In June 2021, results from a preclinical study jointly conducted by Antengene, American biopharmaceutical company Karyopharm Therapeutics andUniversity of Georgia College of Veterinary Medicine has been published in a paper titled "selinexor, ...
2021-07-26 08:44
3789
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI321 (Anti-PD-1/TIGIT Bispecific Antibody) in Patients with Advanced Malignant Tumors
SAN FRANCISCO and SUZHOU, China, July 25, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2021-07-26 08:00
7658
FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical Trials Of CoviDTH
VANCOUVER, British Columbia, July 22, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTCQB: BVAXF)("BioVaxys"), is pleased to announce today that the US Food and Drug Administration ("FDA") has provided its official Written Response to the Company's request for a Pre-IN...
2021-07-22 21:50
10504
Intas Enters into an Exclusive License Agreement with Meiji and Dong-A ST to commercialize DMB-3115 (Proposed Biosimilar to Ustekinumab)
Intas Pharmaceuticals Ltd continues to pledge their commitment to increasing access to high quality medicines by entering into an exclusive license agreement AHMEDABAD, India, July 22, 2021 /PRNewswire/ -- Intas Pharmaceuticals Ltd continues to pledge their commitment to increasing access to high...
2021-07-22 13:00
4120
Week's Top Stories
Most Reposted
Digital Identity Co. Modernizes Thailand Immigration Bureau Services with AWS
[Picked up by 314 media titles]
2026-05-28 15:06The Philippines Sets a New Standard in Muslim-Friendly Tourism
[Picked up by 290 media titles]
2026-05-26 10:30
Asian Society of Cardiovascular Imaging and Philips sign MOU to strengthen imaging capabilities across Asia Pacific
[Picked up by 289 media titles]
2026-05-28 17:34
ASEAN Business Advisory Council (ASEAN-BAC) and AVPN Establish Regional Platform to Strengthen Corporate Social Investment and Cross-Sector Collaboration Across Southeast Asia
[Picked up by 288 media titles]
2026-05-28 10:06Agoda and Philippines Department of Tourism announce strategic partnership to promote and elevate tourism
[Picked up by 287 media titles]
2026-05-27 09:16
Most Read
/DISREGARD RELEASE: Yangzhou Home Ka Crafts Co., Ltd./
2026-05-29 09:19
7048
ISDN's IDI Dynamics debuts high-speed laser marker for semiconductor assembly and test (OSAT)
2026-05-26 08:40
6077
NYSE Content Update: Mastercard Celebrates Two Decades as NYSE-Listed Company
2026-05-26 21:04
6068
